Nylidrin | CAS#447-41-6 | Beta-adrenergic agonist

MedKoo Cat#: 584297 | Name: Nylidrin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nylidrin is a beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.

Chemical Structure

Nylidrin

CAS#447-41-6

Theoretical Analysis

MedKoo Cat#: 584297

Name: Nylidrin

CAS#: 447-41-6

Chemical Formula: C19H25NO2

Exact Mass: 299.1885

Molecular Weight: 299.41

Elemental Analysis: C, 76.22; H, 8.42; N, 4.68; O, 10.69

Price and Availability

Size	Price	Availability
5mg	USD 210.00	2 Weeks
10mg	USD 340.00	2 Weeks
25mg	USD 540.00	2 Weeks
50mg	USD 810.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Nylidrin; Buphenine;

IUPAC/Chemical Name

Benzenemethanol, 4-hydroxy-alpha-(1-((1-methyl-3-phenylpropyl)amino)ethyl)-

InChi Key

PTGXAUBQBSGPKF-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3

SMILES Code

OC(C(NC(C)CCC1=CC=CC=C1)C)C2=CC=C(O)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Nylidrin is a beta-adrenergic agonist.

In vitro activity:

Nylidrin-induced elevation of cellular cAMP in purified rat mast cells shows no correlation with nylidrin-induced inhibition of histamine release. Thus, nylidrin hydrochloride inhibits release of histamine from mast cells by a novel, non-adrenergic mechanism, which is not dependent on increased levels of cAMP. Reference: Int Arch Allergy Appl Immunol. 1983;70(4):303-10. https://pubmed.ncbi.nlm.nih.gov/6186609/

In vivo activity:

Body weight changes and survival rates confirmed that nylidrin not only mitigated body weight loss induced by viral infection (Figure 5A), but also prevented mortality: complete survival (100%) was comparable to that in the OSV-P-treated group (Figure 5B). In contrast, mice infected with the vehicle-treated maPR8 died between days 9 and 11. Taken together, these findings suggest that nylidrin protects mice from viral infection in vivo by directly targeting the HA2 function of influenza A virus (H1N1). Reference: Viruses. 2020 May 25;12(5):581. https://pubmed.ncbi.nlm.nih.gov/32466302/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	100.00
	DMSO	30.0	100.00
	DMSO:PBS (pH 7.2) (1:7)	0.1	0.40

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 299.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Coutts SM, Khandwala A, Weinryb I. Antiallergic activity of nylidrin hydrochloride (RHC 3432-A). II. A lack of correlation between inhibition of mediator release and levels of cyclic AMP. Int Arch Allergy Appl Immunol. 1983;70(4):303-10. PMID: 6186609. 2. Khandwala A, Coutts SM, Weinryb I. Antiallergic activity of nylidrin hydrochloride (RHC 3432-A). I. Effect on release of histamine in vitro from rat peritoneal mast cells, guinea pig lung slices and human basophils. Int Arch Allergy Appl Immunol. 1983;70(4):295-302. PMID: 6186608. 3. Jang Y, Shin JS, Lee JY, Shin H, Kim SJ, Kim M. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12(5):581. doi: 10.3390/v12050581. PMID: 32466302; PMCID: PMC7290441.

In vitro protocol:

In vivo protocol:

1. Jang Y, Shin JS, Lee JY, Shin H, Kim SJ, Kim M. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12(5):581. doi: 10.3390/v12050581. PMID: 32466302; PMCID: PMC7290441.

1: Jang Y, Shin JS, Lee JY, Shin H, Kim SJ, Kim M. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12(5):581. doi: 10.3390/v12050581. PMID: 32466302; PMCID: PMC7290441. 2: Whittemore ER, Ilyin VI, Konkoy CS, Woodward RM. Subtype-selective antagonism of NMDA receptors by nylidrin. Eur J Pharmacol. 1997 Oct 22;337(2-3):197-208. doi: 10.1016/s0014-2999(97)01292-2. PMID: 9430414. 3: Coté CJ. Nylidrin (Arlidin) poisoning. Pediatrics. 1974 Apr;53(4):570-1. PMID: 4823333. 4: Goldstein SE, Birnbom F. Nylidrin HCL in the treatment of symptoms of the aged: a double-blind placebo controlled study. J Clin Psychiatry. 1979 Dec;40(12):520-4. PMID: 500575. 5: Abel PW, Fox AW, Minneman KP. Effects of isoxuprine and nylidrin on adrenoreceptors in rat vas deferens. J Auton Pharmacol. 1985 Sep;5(3):213-9. doi: 10.1111/j.1474-8673.1985.tb00122.x. PMID: 2997229. 6: Yen TT, Pearson DV. Nylidrin: a potent anti-hypertensive agent in hypertensive rats. Res Commun Chem Pathol Pharmacol. 1979 Jan;23(1):11-28. PMID: 441505. 7: Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2020 Oct 16;10(10):CD005262. doi: 10.1002/14651858.CD005262.pub4. PMID: 33063850; PMCID: PMC8094235. 8: Mittag TW, Tormay A, Messenger M, Podos SM. Ocular hypotension in the rabbit. Receptor mechanisms of pirbuterol and nylidrin. Invest Ophthalmol Vis Sci. 1985 Feb;26(2):163-9. PMID: 2857689. 9: Kurki T, Eronen M, Lumme R, Ylikorkala O. A randomized double-dummy comparison between indomethacin and nylidrin in threatened preterm labor. Obstet Gynecol. 1991 Dec;78(6):1093-7. PMID: 1945214. 10: Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2015 Sep 29;9(9):CD005262. doi: 10.1002/14651858.CD005262.pub3. Update in: Cochrane Database Syst Rev. 2020 Oct 16;10:CD005262. doi: 10.1002/14651858.CD005262.pub4. PMID: 26417854; PMCID: PMC6513423. 11: BASAR D, JACOBSON JH. The effects of a new drug, nylidrin, upon the electroretinogram. AMA Arch Ophthalmol. 1956 Dec;56(6):865-8. doi: 10.1001/archopht.1956.00930040877009. PMID: 13371993. 12: Souney PF, Kaul AF, Osathanondh R. Pharmacotherapy of preterm labor. Clin Pharm. 1983 Jan-Feb;2(1):29-44. PMID: 6136361. 13: Garetz FK, Baron JJ, Barron PB, Bjork AE. Efficacy of nylidrin hydrochloride in the treatment of cognitive impairment in the elderly. J Am Geriatr Soc. 1979 May;27(5):235-6. doi: 10.1111/j.1532-5415.1979.tb06039.x. PMID: 372292. 14: Korein J, Geller M, Rosenblum WI, Levidow L. Effects of a vasoactive drug (nylidrin HCl) on the response of the electroencephalogram to hyperventilation. Arch Neurol. 1966 Feb;14(2):202-7. doi: 10.1001/archneur.1966.00470080086013. PMID: 4952446. 15: Accetto B. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator- nylidrin. Am Heart J. 1982 May;103(5):864-9. doi: 10.1016/0002-8703(82)90401-x. PMID: 7041579. 16: Khandwala A, Coutts SM, Weinryb I. Antiallergic activity of nylidrin hydrochloride (RHC 3432-A). I. Effect on release of histamine in vitro from rat peritoneal mast cells, guinea pig lung slices and human basophils. Int Arch Allergy Appl Immunol. 1983;70(4):295-302. PMID: 6186608. 17: Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary S, Dhore SV, Ghonmode S, Balwani S, Mankar M, Tiwari M, Parikh RV. Review of drug treatment of oral submucous fibrosis. Oral Oncol. 2012 May;48(5):393-8. doi: 10.1016/j.oraloncology.2011.11.021. Epub 2011 Dec 27. PMID: 22206808. 18: Cook P, James I. Cerebral vasodilators (second of two parts). N Engl J Med. 1981 Dec 24;305(26):1560-4. doi: 10.1056/NEJM198112243052604. PMID: 7031468. 19: MacAlpin R. Treatment of vasospastic angina. Cardiovasc Clin. 1983;14(1):129-72. PMID: 6137279. 20: TREPTOW KR, AFFLECK DC, ROEHL CA, SOELLING WM. NYLIDRIN HYDROCHLORIDE IN SENILE ARTERIOSCLEROSIS. Arch Neurol. 1963 Aug;9:142-6. doi: 10.1001/archneur.1963.00460080052007. PMID: 14054151.